Close Menu

The Scan

To Keep Up

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

Support for Another

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

New Prototype Test

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.

Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.

The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.

Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.

In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.

The New York Times writes that the unfilled top spot at the US Food and Drug Administration is "glaring."

Boost to Surveillance

The Canadian COVID-19 Genomics Network aims to increase its genomic surveillance of emerging SARS-CoV-2 strains, the Canadian Press reports.

No New Concerns

Reuters reports that no serious safety concerns have been identified in the first month of SARS-CoV-2 vaccinations in the US.

In PLOS this week: actionable pharmacogenetic variants in Hong Kong population, role of defective viral genomes, and more.

Researchers have cloned the endangered black-footed ferret, the New York Times reports.

A High-Reaching ARIA

According to BBC News, the UK is to launch its new "high-risk" science agency.

Same Coyote, Again

DNA testing ties one coyote linked to three previous attacks to a new biting incident in the Bay Area, the San Francisco Chronicle reports.

In Science this week: cell-free DNA from urine explored to help diagnoses, more.

Lower Response

Two studies indicated that the SARS-CoV-2 vaccines from Pfizer-BioNTech and Moderna have lower neutralizing antibody responses to the B.1.351 viral lineage, according to the Washington Post.

The Chronicle of Higher Education reports that the number of international graduate students in the US has fallen during the COVID-19 pandemic.

CMS Nominee

According to Politico, President Joe Biden is to nominate Chiquita Brooks-LaSure to lead the Centers for Medicare and Medicaid Services.

In Nature this week: analysis of SARS-CoV-2 genomes uncovered substrains in the US.

The AP reports that a bill introduced to the US House of Representatives would provide $1.75 billion to sequence SARS-CoV-2 samples to spot viral changes.

The UK has given the go-ahead to a SARS-CoV-2 human challenge trial, Reuters reports.

Pages

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.